The paper proposed a strategic roadmap with inputs and comments from interested economies and agencies such as the U.S. Food and Drug Administration (FDA), the Thai, Korean and Taiwanese FDAs, the European Medicines Agency, Health Canada, and Therapeutic Goods Administration Australia.